(Q34743481)

4 August 2017

title

Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium (English)

1 reference

4 August 2017

main subject

phase I clinical trial

0 references

dasatinib monohydrate

1 reference

1 reference

1 reference

Frank M Balis

4

0 references

Susan M Blaney

2

object named as

Susan M Blaney

1 reference

4 August 2017

Richard Aplenc

1

1 reference

4 August 2017

Lewis C Strauss

3

1 reference

4 August 2017

Suzanne Shusterman

5

1 reference

4 August 2017

Ashish Mark Ingle

6

1 reference

4 August 2017

Shruti Agrawal

7

1 reference

4 August 2017

Junfeng Sun

8

1 reference

4 August 2017

John J Wright

9

1 reference

4 August 2017

Peter C Adamson

10

1 reference

4 August 2017

language of work or name

English

0 references

publication date

24 January 2011

1 reference

Journal of Clinical Oncology

4 August 2017

published in

1 reference

4 August 2017

volume

29

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

839-844

1 reference

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Initial testing of dasatinib by the pediatric preclinical testing program

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Measures of response: RECIST, WHO, and new alternatives

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Overriding imatinib resistance with a novel ABL kinase inhibitor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Metabolism and disposition of dasatinib after oral administration to humans

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068059

9 December 2018

Identifiers

DOI

10.1200/JCO.2010.30.7231

1 reference

4 August 2017

1 reference

4 August 2017

1 reference